. Author manuscript; available in PMC: 2015 Jul 23.

Published in final edited form as: J Urol. 2015 Feb 11;194(1):230–237. doi: 10.1016/j.juro.2015.02.036

Table 1. Survivin silencing enhances MMC activity in vitro and in vivo.

Cultured RT4 cells and mice bearing RT4 xenograft tumors were treated with MMC, nontarget siRNA and survivin siRNA (siRNA were delivered in PPCat), as described in the legends of Figures 1 and 3. For the in vitro studies, the MMC concentration was 3 µM and the siRNA concentration was 100 nM. For the in vivo studies, the MMC dose was 3 mg/kg given every 4 days for a total of 3 doses and the siRNA dose was 1 nmole given 2 days after each MMC treatment.

Group	A. In Vitro results		B. In Vivo results
	Survivin expression mean±SD (3 experiments, 3 samples each)		Time for 50% tumor size increase, median (range), days	Survivin protein level, % of control (n=3–5)	% Ki67- positive cells (n=3–5)	% TUNEL- positive cells (n=3–5)
	mRNA	Protein	Time for 50% tumor size increase, median (range), days	Survivin protein level, % of control (n=3–5)	% Ki67- positive cells (n=3–5)	% TUNEL- positive cells (n=3–5)
Control	1.00 ± 0.10	1.00 ± 0.09	8 (8-12, n=5)	100 ± 21	66 ± 5	4 ± 1
PPCat-siNT	1.08 ± 0.05	0.99 ± 0.25	12 (8-12, n=5)	90 ± 23	65 ± 7	5 ± 4
PPCat-siSurvivin	0.82 ± 0.02^*	0.58 ± 0.10^*	12 (8-12, n=5)	55 ± 15^*	60 ± 6	4 ± 2
MMC	1.47 ±0.34^*	1.52 ± 0.08^*	37 (23-44, n=10)^*	302 ± 18^*	38 ± 6^*	31 ± 4^*
MMC + PPCat-siNT	1.53 ± 0.24^*	1.33 ± 0.06^*	37 (23-44, n=5)^*	240 ± 45^*	41 ± 8^*	33 ± 7^*
MMC + PPCat-siSurvivin	1.13 ± 0.17^**	0.90 ± 0.04^**	44 (37-58, n=10)^***	90 ± 28^**	16 ± 5^***	59 ± 6^***

p<0.05 vs. the untreated control and PPCat-siNT control.

^**

p<0.05 vs. MMC and MMC+PPCat-siNT, but not different from untreated control and PPCat-siNT control.

^***

p<0.05 vs. all other groups.